奥扎格雷钠联合低分子肝素治疗进展性脑梗死疗效观察

目的观察奥扎格雷钠联合低分子肝素治疗进展性脑梗死的疗效及安全性。方法将85例进展性脑梗死患者随机分成联合组43例及对照组42例。2组均给予常规治疗及酌情对症处理,同时联合组给予奥扎格雷钠联合低分子肝素钠;对照组仅给予低分子肝素钠。2组患者于治疗前、治疗后14天依据美国国立卫生院卒中量表(NIHSS)评分及日常生活活动能力(ADL)评分评定神经功能缺损程度。结果治疗14 d后,2组患者NIHSS及ADL评分均有显著改善,联合组改善优于对照组(P<0.05),联合组及对照组显效率分别为69.77%及47.62%(P<0.05)。2组患者均无消化道出血、颅内出血等不良反应发生。结论奥扎格雷钠联合低分子肝素钠治疗进展性脑梗死是一种有效、安全的治疗方法,值得临床推广使用。

A clinical study of sodium ozagrel injection combined with low molecular weight heparin sodium on progressive cerebral infarction

Objective To observe the therapeutic effect of sodium ozagrel injection combined with low molecular weight heparin sodium in the treatment of progressive cerebral infarction.Methods Eighty patients were randomly divided into treatment group and control group,which were administered sodium ozagrel+ low molecular weight heparin sodium and low molecular weight heparin sodium,respectively.The degree of neurological deficit were assessed according to the U.S.National Institutes of Health Stroke Scale(NIHSS) score and activities of daily living(ADL) in two groups before treatment,and 14 days after treatment.Results The excellence rates in the treatment and control group were 69.77% and 47.62%,respectively 14 days after treatment. The rate of improvement in the combined group was better than that of the control group(P<0.05).No complications of gastrointestinal bleeding,intracranial hemorrhage were identifed in both groups.Conclusion Sodium ozagrel injection combined with low molecular weight heparin sodium is safe and reliable in treating progressive cerebral infarction,which is worthy of clinical use.